Safety profile of antidepressant for Japanese adults with major depressive disorder: A systematic review and network meta-analysis

Affiliations

¹ Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
² Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, University, Mississippi, USA.
³ Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
⁴ Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.
⁵ Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
⁶ Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Japan.
⁷ Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
⁸ Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.

Free article

Taro Kishi et al. Psychiatry Clin Neurosci. 2024 Feb.

Free article

. 2024 Feb;78(2):142-144.

doi: 10.1111/pcn.13622. Epub 2023 Dec 10.

¹ Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan.
² Department of Communication Sciences and Disorders, School of Applied Sciences, University of Mississippi, University, Mississippi, USA.
³ Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Toyoake, Japan.
⁴ Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan.
⁵ Faculty of Pharmaceutical Sciences, Kobe Gakuin University, Kobe, Japan.
⁶ Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Japan.
⁷ Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan.
⁸ Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan.

No abstract available

References

1. JSMD. Treatment guideline for major depressive disorder. https://www.secretariat.ne.jp/jsmd/ 2016.
1. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. Lancet 2018; 391: 1357-1366.
1. Zhang J, Mathis MV, Sellers JW et al. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine. J. Clin. Psychiatry 2015; 76: 8-14.
1. Montgomery SA. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008; 13: 27-33.
1. Milosavljevic F, Bukvic N, Pavlovic Z et al. Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: A systematic review and meta-analysis. JAMA Psychiatry 2021; 78: 270-280.